share_log

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $71

Benzinga Real-time News ·  Sep 30, 2022 08:32

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $75 to $71.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment